1199 related articles for article (PubMed ID: 16990856)
1. Topoisomerase I inhibitors: camptothecins and beyond.
Pommier Y
Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
[TBL] [Abstract][Full Text] [Related]
2. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
3. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
5. [Molecular determinants of response to topoisomerase I inhibitors].
Pourquier P; Lansiaux A
Bull Cancer; 2011 Nov; 98(11):1287-98. PubMed ID: 22049384
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
7. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
[TBL] [Abstract][Full Text] [Related]
8. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
[TBL] [Abstract][Full Text] [Related]
9. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
10. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors.
Pommier Y; Jenkins J; Kohlhagen G; Leteurtre F
Mutat Res; 1995 Sep; 337(2):135-45. PubMed ID: 7565862
[TBL] [Abstract][Full Text] [Related]
11. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Hartmann JT; Lipp HP
Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
[TBL] [Abstract][Full Text] [Related]
14. [A symphony for the camptothecins].
Lansiaux A; Bailly C
Bull Cancer; 2003 Mar; 90(3):239-45. PubMed ID: 12801826
[TBL] [Abstract][Full Text] [Related]
15. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
16. Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A; Pommier Y
Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
[TBL] [Abstract][Full Text] [Related]
17. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
[TBL] [Abstract][Full Text] [Related]
18. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
[TBL] [Abstract][Full Text] [Related]
19. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.
Adachi N; So S; Koyama H
J Biol Chem; 2004 Sep; 279(36):37343-8. PubMed ID: 15218034
[TBL] [Abstract][Full Text] [Related]
20. Diversity of DNA topoisomerases I and inhibitors.
Pommier Y
Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]